Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||renal cell carcinoma||not applicable||Alpha 2 Interferon + Bevacizumab||FDA approved||Actionable||In a Phase III clinical trial that supported FDA approval, treatment with the combination of Avastin (bevacizumab) and Roferon (interferon alpha 2a) resulted in improved progression-free survival in patients with metastatic renal cell carcinoma compared to Roferon (interferon alpha 2a) with placebo (PMID: 20061402).||20061402 detail...|